Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

12.8K
The metastatic spread of cancer is the major cause of cancer-related deaths. We provide an in-depth description of our survival surgery methodology for establishing a “patient-like” orthotopic syngeneic mouse model system for studying the mechanisms of metastasis in solid organ...
12.8K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

6.1K
Transarterial chemoembolization (TACE) is the standard therapy for patients in the intermediate stage of hepatocellular carcinoma and is typically performed through femoral artery access. Compared with transfemoral access, transradial access (TRA) can decrease the rate of bleeding complications and improve patient tolerance. A method is presented here to perform transarterial chemoembolization via radial artery...
6.1K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

37.0K
Human tumor xenografts in immunodeficient mice are valuable tools to study cancer biology. Specific protocols to generate subcutaneous and intrahepatic xenografts from human hepatocellular carcinoma cells or tumor fragments are described. Liver regeneration induced by partial hepatectomy in recipient mice is presented as a strategy to facilitate intrahepatic...
37.0K
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

2.7K
Here, we present a protocol to create orthotopic hepatocellular carcinoma xenografts with and without hepatic artery ligation and perform non-invasive positron emission tomography (PET) imaging of tumor hypoxia using [18F]Fluoromisonidazole ([18F]FMISO) and [18F]Fluorodeoxyglucose...
2.7K
Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery07:25

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery

2.5K
We provide a comprehensive overview and refinement of existing protocols for hepatocellular carcinoma (HCC) organoid formation, encompassing all stages of organoid cultivation. This system serves as a valuable model for the identification of potential therapeutic targets and the assessment of drug candidate...
2.5K
Exploring the Potential of Mesenchymal Stem Cell Sheet on The Development of Hepatocellular Carcinoma In Vivo10:18

Exploring the Potential of Mesenchymal Stem Cell Sheet on The Development of Hepatocellular Carcinoma In Vivo

6.2K
Here, we present a protocol to develop an in vivo cancer model using cell sheet technology. Such a model could be very useful for the evaluation of anticancer...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis.

Journal of the National Cancer Institute·2026
Same author

Immune Checkpoint Inhibitor Outcomes Across Child-Pugh A, B, and C Hepatocellular Carcinoma: A Real-World Integrated Health-System Cohort.

Cancer treatment and research communications·2026
Same author

ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma.

Annals of surgical oncology·2026
Same author

Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma.

Annals of surgical oncology·2026
Same author

Exercise reduces hepatic pre-metastatic niche formation via TREM-1 signaling in kupffer cells.

BMC medicine·2026
Same author

Refining the boundaries of resectability for colorectal cancer liver metastases with extrahepatic disease-surgical lessons from a nationwide analysis.

Hepatobiliary surgery and nutrition·2026

Related Experiment Video

Updated: Jan 20, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

12.8K

Evolving Surgical Options for Hepatocellular Carcinoma.

Gregory C Wilson1, David A Geller1

  • 1Department of Surgery, Liver Cancer Center, University of Pittsburgh Medical Center, 3471 Fifth Avenue, Suite 300, Pittsburgh, PA, USA.

Surgical Oncology Clinics of North America
|September 2, 2019
PubMed
Summary

Surgical resection and liver transplant are key treatments for hepatocellular carcinoma. Laparoscopic liver resection offers similar long-term results to open surgery with better short-term outcomes.

Keywords:
Barcelona Clinic Liver CancerHepatocellular carcinomaLaparoscopic liver resectionLiver transplantRadiofrequency ablation

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.1K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

37.0K

Related Experiment Videos

Last Updated: Jan 20, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

12.8K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.1K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

37.0K

Area of Science:

  • Hepatobiliary Surgery
  • Surgical Oncology
  • Transplant Surgery

Background:

  • Hepatocellular carcinoma (HCC) treatment relies on surgical resection and liver transplant.
  • Treatment decisions are complex, influenced by cirrhosis, tumor stage, and patient health.
  • A multidisciplinary team approach is crucial for optimal HCC management.

Purpose of the Study:

  • To evaluate the expanding role and outcomes of laparoscopic liver resection for HCC.
  • To compare laparoscopic versus open liver resection for HCC.
  • To reaffirm the role of liver transplant in specific HCC patient populations.

Main Methods:

  • Comparative analysis of laparoscopic and open liver resection for HCC.
  • Assessment of short-term outcomes (blood loss, hospital stay) and long-term oncologic results.
  • Review of indications for liver transplant in cirrhotic patients with HCC.

Main Results:

  • Laparoscopic liver resection shows comparable long-term oncologic outcomes to open resection.
  • Laparoscopic surgery demonstrates improved short-term results, including reduced blood loss and shorter hospital stays.
  • Liver transplant is the preferred treatment for cirrhotic patients with HCC and portal hypertension.

Conclusions:

  • Laparoscopic liver resection is a viable and expanding option for HCC treatment.
  • Laparoscopic resection offers significant short-term benefits over open resection for HCC.
  • Liver transplantation remains the gold standard for select cirrhotic patients with HCC.